Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HeartSciences Inc. (HSCS)
USD2.50
-0.12 (-4.58%)
US NASDAQ Healthcare Medical - Devices
Address
550 Reserve Street 76092-1552
Southlake, TX, US
Southlake, TX, US
CEO
Andrew Simpson
Website
heartsciences.com
IPO
2022-06-16
CIK 1468492 ISIN US42254E3027
Also trades on
NASDAQ Capital Market · HSCS (USD)
NASDAQ Capital Market · HSCSW (USD)
Description
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.50
-0.12 (-4.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.97
Float Shares
1.96M
Free Float %
90.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.96% | -15.66% | -14.36% | -40.14% | -37.69% | -45.95% | -52.69% | -98.36% | -99.02% | -99.02% | -99.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
2.50
Low
3.00
+20.0%
Consensus
3.00
+20.0%
Median
3.00
+20.0%
High
3.00
+20.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
3.00
+20.0%
|
Quality scores
Altman Z-Score
-18.21
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-76.6%
-
EPS growth Medical - Devices: +28.5%+50.2% ★ Q1'26: +75.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-187,346.5%
-
EBIT margin Medical - Devices: +6.2%-189,994.9%
-
ROIC Medical - Devices: +3.3%-395.0% Q1'26: +0.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+166.2% Q1'26: +220.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.37× Q1'26: -0.51× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 1 Rev. Ana. 1 EPS Ana. |
Apr 2027 1 Rev. Ana. 1 EPS Ana. |
Apr 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
5.2K
est: 2.5K (+106.0%)
|
18.6K
est: 18.6K (+0.0%)
|
4.4K
est: 50.0K (-91.3%)
|
50.0K
33.8K – 66.2K
+0.0% YoY
|
350.0K
236.6K – 463.4K
+600.0% YoY
|
3.20M
3.18M – 3.23M
+814.3% YoY
|
| EBITDA |
-6.08M
est: -2.5K (-243,268.0%)
|
-6.16M
est: -18.6K (-32,996.7%)
|
-8.14M
est: -50.0K (-16,173.6%)
|
-50.0K
-66.2K – -33.8K
+0.0% YoY
|
-350.0K
-463.4K – -236.6K
-600.0% YoY
|
-3.20M
-3.23M – -3.18M
-814.3% YoY
|
| EBIT |
-6.11M
est: -2.5K (-244,344.6%)
|
-6.25M
est: -18.6K (-33,508.2%)
|
-8.26M
est: -50.0K (-16,429.6%)
|
-50.0K
-66.2K – -33.8K
+0.0% YoY
|
-350.0K
-463.4K – -236.6K
-600.0% YoY
|
-3.20M
-3.23M – -3.18M
-814.3% YoY
|
| Net Income |
-6.35M
est: -72.71M (+91.3%)
|
-6.61M
est: -13.13M (+49.7%)
|
-8.77M
est: -8.77M (+0.0%)
|
-3.23M
-4.59M – -1.87M
+63.2% YoY
|
-2.83M
-4.02M – -1.64M
+12.4% YoY
|
-2.07M
-2.95M – -1.20M
+26.7% YoY
|
| SGA |
3.63M
est: 980.2K (+270.1%)
|
3.34M
est: 7.13M (-53.1%)
|
3.84M
est: 19.17M (-80.0%)
|
19.17M
12.96M – 25.38M
+0.0% YoY
|
134.22M
90.75M – 177.69M
+600.0% YoY
|
1.23B
1.22B – 1.24B
+814.3% YoY
|
| EPS |
-6,173.88
est: -77.50 (-7,866.3%)
|
-18.74
est: -13.99 (-34.0%)
|
-9.34
est: -9.09 (-2.8%)
|
-3.44
-4.89 – -1.99
+62.2% YoY
|
-3.02
-4.28 – -1.75
+12.4% YoY
|
-2.21
-3.14 – -1.28
+26.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.76B
OE per share TTM
-1,923.79
Owner's Yield
-108,985.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,854.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
6
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EIN 75-2321197 | 5.24M | 8.10% | 5.24M | — | 5.24M | — | CO | Texas | 2023-12-11 | ↗ |
| 2 | John H. Matthews | 5.24M | 8.10% | 5.24M | — | 5.24M | — | IN | Texas | 2023-12-11 | ↗ |
| 3 | EIN 13-6171197 | 4.85M | 9.90% | 4.85M | — | 4.85M | — | CO | New York | 2023-11-27 | ↗ |
| 4 | Andrew Simpson | 567.2K | 5.50% | — | — | 567.2K | — | IN | — | 2023-06-14 | ↗ |
| 5 | Mark Hilz | 558.2K | 5.40% | — | — | 558.2K | — | IN | — | 2023-06-14 | ↗ |
| 6 | 46-4248304 | — | 0.00% | — | — | — | — | HC | New York | 2023-11-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 29.2K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
30.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+30,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | Wells David R. | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2026-01-12 | Bent Bruce | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-12-22 | Watson Danielle | Officer | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-12-22 | Szymczak Brian | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-12-22 | HILZ MARK T | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | D | ↗ |
| 2025-11-28 | Simpson Andrew | Director / Officer | A-Award | A | Common Stock, $0.001 par value | 70,000 | 0.00 | 70.00 | 74,382 | D | ↗ |
| 2025-07-29 | HILZ MARK T | Director / Officer | S-Sale | D | Common Stock, $0.001 par value | 4,416 | 3.54 | 15.6K | 4,752 | D | ↗ |
| 2025-07-09 | Wells David R. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 4.37 | 109.3K | 25,000 | D | ↗ |
| 2025-07-09 | Watson Danielle | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 4.37 | 109.3K | 25,000 | D | ↗ |
| 2025-07-09 | Szymczak Brian | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 4.37 | 109.3K | 25,000 | D | ↗ |
| 2025-07-09 | Simpson Andrew | Director / Officer | A-Award | A | Restricted Stock Units | 68,750 | 0.00 | — | 68,750 | D | ↗ |
| 2025-07-09 | HILZ MARK T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 4.37 | 983.3K | 225,000 | D | ↗ |
| 2025-07-09 | Bent Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 4.37 | 109.3K | 25,000 | D | ↗ |
| 2025-01-16 | Wells David R. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 6,000 | 3.33 | 20.0K | 6,000 | D | ↗ |
| 2025-01-16 | Watson Danielle | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 3.33 | 30.0K | 9,000 | D | ↗ |
| 2025-01-16 | Szymczak Brian | Director | A-Award | A | Employee Stock Option (Right to Buy) | 6,000 | 3.33 | 20.0K | 6,000 | D | ↗ |
| 2025-01-16 | Simpson Andrew | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 45,000 | 3.33 | 149.9K | 45,000 | D | ↗ |
| 2025-01-16 | HILZ MARK T | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 45,000 | 3.33 | 149.9K | 45,000 | D | ↗ |
| 2025-01-16 | Bent Bruce | Director | A-Award | A | Employee Stock Option (Right to Buy) | 6,000 | 3.33 | 20.0K | 6,000 | D | ↗ |
| 2024-08-12 | Simpson Andrew | Director / Officer | J-Other | A | Common Stock, $0.001 par value | 17 | 0.00 | — | 7,629 | — | ↗ |
| 2022-12-28 | Wells David R. | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-06-14 | Watson Danielle | Officer | — | D | Employee Stock Option (Right to Buy) | 4,545 | 3.47 | 15.8K | 0 | — | ↗ |
| 2022-06-14 | Szymczak Brian | Director | — | D | Director Stock Option (Right to Buy) | 1,894 | 3.47 | 6.6K | 0 | — | ↗ |
| 2022-06-14 | Simpson Andrew | Director / Officer | — | D | Employee Stock Option (Right to Buy) | 7,576 | 15.18 | 115.0K | 0 | — | ↗ |
| 2022-06-14 | Kanouff Patrick | Director | — | D | Common Stock | 0 | 0.00 | — | 7,882 | — | ↗ |
| 2022-06-14 | HILZ MARK T | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 4,040 | — | ↗ |
| 2022-06-14 | Bent Bruce | Director | — | I | Common Stock | 0 | 0.00 | — | 1,638 | — | ↗ |
| 2022-02-28 | Kanouff Patrick | Director | — | D | Warrants | 6,464 | 5.16 | 33.4K | 0 | — | ↗ |
| 2021-11-17 | Szymczak Brian | Director | — | D | Warrants | 30 | 2.89 | 86.70 | 0 | — | ↗ |
| 2021-11-17 | Simpson Andrew | Director / Officer | — | D | Warrants | 30 | 2.89 | 86.70 | 0 | — | ↗ |
| 2021-11-17 | HILZ MARK T | Director / Officer | — | D | Warrants | 30 | 2.89 | 86.70 | 0 | — | ↗ |
| 2013-08-23 | Simpson Andrew | Director / Officer | — | D | Warrants | 758 | 3.47 | 2.6K | 0 | — | ↗ |
| 2013-08-23 | HILZ MARK T | Director / Officer | — | D | Warrants | 644 | 3.47 | 2.2K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.5K
Shares Outstanding
2.17M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors | 345.8K | 65.0K | — | 116.3K | — | — | 527.2K | 22.07% | ↗ |
| 2 | 2025 | Mark Hilz Chief Operating Officer and Secretary | 337.9K | 65.0K | — | 116.3K | — | — | 519.2K | 22.41% | ↗ |
| 3 | 2025 | Danielle Watson Chief Financial Officer and Treasurer | 203.7K | 30.0K | — | 23.3K | — | — | 256.9K | 9.06% | ↗ |
| 4 | 2024 | Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 5 | 2024 | Mark Hilz Chief Operating Officer and Secretary | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 6 | 2024 | Danielle Watson Chief Financial Officer and Treasurer | 179.3K | — | — | — | — | — | 179.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew Simpson | Chief Executive Officer, President & Chairman of the Board of Directors | 410.8K | male |
| Mark T. Hilz | Chief Operating Officer, Secretary & Director | 402.9K | male |
| Danielle Watson | Chief Financial Officer & Treasurer | 233.7K | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HSCS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
